BioSpace News Archive

In line with its continued growth, inVibe Labs, a market research innovator dedicated to changing the way healthcare organizations listen to their customers, today announced the appointments of Kathryn Ticknor as Head of Research, Mariana Posada as Research Manager, and Zach Rigotti as Software Engineer.

Torque, an immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, and Thermo Fisher Scientific Inc. (NYSE: TMO), today announced a collaboration to build a dedicated Slipstream™ manufacturing facility for high-efficiency production of Torque’s Deep-Primed T cell immunotherapies.

As part of its ongoing commitment to building healthier communities, CVS Health (NYSE: CVS) today announced it will be offering no cost “Know Your Numbers” heart health screenings at MinuteClinic, the company’s retail medical clinic, every Thursday in February, including Valentine’s Day.

Enzyvant, today announced that abstracts highlighting the development of its investigational RVT-801 program and the natural history of Farber disease will be presented in Orlando, Florida, by Enzyvant and its collaborators at the 2019 WORLDSymposium™, an annual conference focused on lysosomal diseases.

He most recently worked at Radiant/Synexus, where he was the vice president of business development and had the opportunity to work closely with 180 sites across the world.

Company Also Sweeps Category Leader Designations for Central Pharmacy Automation Hardware

Dawson brings a wealth of experience in company growth and culture development, as well as talent acquisition and coaching.

Verseon’s precision oral anticoagulants (PROACs) could become the first anticoagulants suitable for long-term co-administration with antiplatelet agents for the prevention of stroke and heart attack in coronary artery disease patients.

The Pacific Brain Tumor Center at Pacific Neuroscience Institute, in collaboration with the John Wayne Cancer Institute at Providence Saint John’s Health Center, is the leading enrollment site for the MDNA55 clinical trial from Medicenna Therapeutics.

DocuSol® Kids is a simple, non-irritating formula that can be used quickly and efficiently.